---
topic: Antithrombotic Strategy / High Bleeding Risk
status: archived-to-lpa-master
last_updated: 2026-06-03
tags: [cardiovascular, antithrombotics, lp(a), gi-bleeding, archived]
priority: important
abstract: >-
  This former standalone antithrombotic page has been folded into ASCVD / Lp(a) Prevention Master and Medication List + Hard Avoids. It remains as a short preserved pointer because aspirin/antiplatelet safety is link-sensitive.
---

# Antithrombotic Strategy — archived pointer

This page is no longer the active owner. Its aspirin/high-Lp(a) evidence summary and high-bleeding-risk net-benefit rule were folded into [ASCVD / Lp(a) Prevention Master](#sec-lp-a) on 2026-05-10, with medication safety still cross-linked from [Medication List + Hard Avoids](#sec-medication-avoid-list).

Preserved core rule, updated after old papers were found: no self-directed aspirin or antiplatelet even though 2024 RPPH Doppler documents mild right-leg PAD/peripheral plaque. Very high Lp(a) plus plaque makes antiplatelet logic tempting, but prior diverticular hemorrhage plus stool-blood/iron history makes bleeding risk real. Antithrombotics are a cardiology + GI decision, especially if obstructive CAD, MI, stroke/TIA, stent, progressive/symptomatic PAD, or clinician-defined chronic coronary disease is documented.

Full original text is preserved in `archive/ascvd-lpa-prevention-originals-2026-05-10.md`.